COVID-19 has had bad repercussions at the whole international populace. Despite there being a not unusualplace aim that ought to have unified assets and efforts, there had been an overwhelmingly big quantity of medical trials which have been registered which are of questionable methodological exceptional. As the very last paper of this Series, we talk how the clinical studies network has replied to COVID-19. We comprehend the remarkable stress that this pandemic has placed on researchers, regulators, and coverage makers, all of whom have been doing their pleasant to transport speedy however appropriately in a time of awesome uncertainty.